MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Betahistine dihydrochloride

CAS No. : 5579-84-0

MCE 站：Betahistine dihydrochloride

产品活性：Betahistine dihydrochloride 是一种口服有效的组胺 H1 受体 (histamine H1 receptor) 激动剂和 H3 受体 (H1 receptor) 的拮抗剂。Betahistine dihydrochloride 用于类风湿性关节炎 (RA) 的研究。

研究领域：GPCR/G Protein  |  Neuronal Signaling  |  Immunology/Inflammation

作用靶点：Histamine Receptor

In Vitro: Betahistine dihydrochloride (0-10 μM) inhibits [¹²⁵I]iodoproxyfan binding to membranes of CHO (rH₃₍₄₄₅₎R) and CHO (hH₃₍₄₄₅₎R) cells with IC₅₀ values of 1.9 μM and 3.3 μM, respectively. Lead to K_i values of 1.4 μM and 2.5 μM, respectively.
Betahistine dihydrochloride (0-10 μM) has a regulating function on cAMP formation in CHO (rH₃₍₄₄₅₎R), CHO (rH₃₍₄₁₃₎R), and CHO (hH₃₍₄₄₅₎R) cells. At low concentrations, betahistine behaves an apparent inverse agonist, and progressively enhances cAMP formation with EC₅₀ values of 0.1 nM, 0.05 nM and 0.3 nM, respectively. In contrast, at concentrations higher than 10 nM, betahistine inhibits cAMP formation with an EC₅₀ value of 0.1 μM in CHO (rH₃₍₄₄₅₎R) and full agonist activity.

In Vivo: Betahistine dihydrochloride (intraperitoneal or oral administration; 0.1-30 mg/kg; single dose) with acute administration has increased tele-methylhistamine (t-MeHA) levels with an ED₅₀ of 0.4 mg/kg, indicating the inverse agonism. Besides, after acute oral administration, it increases t-MeHA levels with an ED₅₀ of 2 mg/kg in male Swissmice.
Betahistine dihydrochloride (oral adminstration; 1 and 5 mg/kg; daily for 3 weeks) attenuates the severity of arthritis and reduces the levels of pro-inflammatory cytokines in the paw tissues of CIA mice.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Endocrinology Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Histamine  |  Clemastine fumarate  |  Amitriptyline hydrochloride  |  Astemizole  |  Fexofenadine hydrochloride  |  Osthole  |  Terfenadine  |  Famotidine  |  Diphenhydramine hydrochloride  |  Levocetirizine dihydrochloride  |  Perphenazine  |  Loratadine  |  Cimetidine  |  Chlorprothixene  |  Lodoxamide  |  Pitolisant hydrochloride  |  Rupatadine Fumarate  |  Desloratadine  |  Latrepirdine dihydrochloride  |  Mianserin hydrochloride  |  Mirtazapine  |  Ebastine  |  Azelastine hydrochloride  |  Ritanserin  |  Chlorpheniramine maleate  |  Mepyramine maleate  |  Cinnarizine  |  Ranitidine hydrochloride  |  Clemizole hydrochloride

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。